Regeneron Pharmaceuticals’ (REGN) second quarter 2014 adjusted earnings (including stock-based compensation expense) of $1.89 per share were well short of the Consensus Estimate of $2.33. The company had earned $1.36 per share in the year-ago quarter. Results were impacted by higher costs. Including one-time items, earnings increased 3.8% to 82 cents per share. A higher…
The outbreak of the deadly and highly infectious Ebola disease in Africa has already claimed multiple lives. According to media reports many health workers including doctors and nurses have also fallen a prey to the worst outbreak of the disease. According to the World Health Organization (WHO), the disease first surfaced in 1976. Among other…
Amgen (AMGN) reported second quarter 2014 earnings of $2.37 per share, well above the Consensus Estimate of $1.99 and the year-ago earnings of $1.88. Total revenues increased 11% to $5,180 million in the second quarter of 2014, beating the Consensus Estimate of $4,875 million. Including one-time items, second quarter earnings increased 22% to $2.01 per…
Vertex Pharmaceuticals Inc.’s (VRTX) second-quarter 2014 loss came in at 79 cents per share (including stock-based compensation expense), much wider than the loss of 21 cents reported in the year-ago quarter. Second quarter 2014 loss was also wider than the Consensus Estimate of a loss of 74 cents. Excluding the impact of stock-based compensation expense,…
In an impressive piece of news on the Stock Market, Celgene (CELG) reported second-quarter 2014 earnings (including stock-based compensation expenses) of 80 cents per share, which surpassed the Market Consensus Estimate by 3 cents. The company’s earnings were 70 cents per share in the year-ago quarter. Figures have been adjusted to reflect the two-for-one stock…
AbbVie Inc (ABBV) reported second quarter 2014 earnings of 82 cents per share, unchanged from the year-ago earnings but surpassing the Consensus Estimate of 76 cents. Revenues increased 5% to $4.926 billion in the second quarter of 2014, surpassing the Consensus Estimate of $4.671 billion. Results were boosted by Humira’s strong performance. Including one-time items,…
